Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)

Trial Profile

Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms LANTERN-1
  • Sponsors Bonti
  • Most Recent Events

    • 23 Aug 2017 Status changed from not yet recruiting to recruiting, according to a Bonti media release.
    • 23 Aug 2017 According to a Bonti media release, interim clinical results from the LANTERN-1 Phase 2 study are expected by year-end 2017.
    • 21 Aug 2017 Planned number of patients changed from 44 to 64.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top